期刊文献+

非霍奇金淋巴瘤治疗前PET/CT中SUV的相关因素研究 被引量:4

CORRELATION ANALYSIS OF THE SUV VALUE IN PRE-THERAPY FDG-PET/CT IN PATIENTS WITH NON-HODGKIN LYMPHOMA
原文传递
导出
摘要 目的探讨非霍奇金淋巴瘤(NHL)在18F-FDG PET/CT检查中标准化摄取值(SUV)的影响因素及与预后的关系。方法分析136例NHL患者全身最大淋巴结的SUVmax与其年龄、B症状、恶性程度、骨髓浸润、临床分期、病灶大小、坏死情况、治疗前血清LDH(psLDH)及Ki-67阳性率的关系及部分因素之间的相关性。采用Wilcoxon检验分析SUVmax与临床病理特征间的关系;采用Spearman秩相关分析SUVmax与病灶大小、Ki-67阳性率及psLDH的相关性。随访71例患者,根据R-IPI将71例患者分为预后非常好、预后好、预后差三组,采用方差分析分析SUVmax与临床预后的关系。结果经Wilcoxon检验发现SUVmax与恶性程度(P=0.0003)、骨髓浸润(P=0.003)、临床分期(P=0.021)、病灶大小(P=0.0001)、坏死情况(P=0.011)、psLDH(P=0.0002)、Ki-67阳性率(P=0.015)有关。经Spearman秩相关分析发现SUVmax与病灶大小、Ki-67阳性率及psLDH呈正相关,相关系数r分别为0.737、0.615、0.691(P<0.05)。通过ROC曲线比较,结果提示SUVmax、psLDH能够较准确地反映NHL的侵袭性,AZ值分别为0.878、0.740。经方差分析发现随访预后3组患者病灶的SUVmax有差异,分别为6.87±2.79、9.69±2.19、18.65±5.95,呈逐渐升高趋势,预后非常好与预后好组的SUVmax明显低于预后差组(P<0.05)。结论 SUVmax与多项临床病理指标有关系,且与病灶大小、Ki-67阳性率及psLDH呈正相关,其中病灶大小对SUVmax影响最明显。另外SUVmax较psLDH诊断侵袭性淋巴瘤的准确性略高。在R-IPI的不同随访预后组中病灶的SUVmax有差异,呈逐渐升高趋势。 Objective To explore the related factors of PET/CT standardized uptake value(SUV)in patients with Non-Hodgkin lymphoma(NHL).Methods Clinical and pathological data of the 136 patients were retrospectively analyzed.Relationships of SUV max in cervical lymph nodes with age,B group,grade malignancy,bone marrow involvement,tumor staging,lesion size,necrosis,pre-treatment serum LDH(psLDH)and positive rate of Ki-67 were observed.Wilcoxon test was used for the clinical characteristics between the two groups.The correlations of SUV max with tumor size,positive rate of Ki-67 and psLDH were analyzed by using Spearman rank correlation.Seventy one patients were followed up according to RIPI,and divided into 3 prognostic groups(very good,good,poor),variance analysis was used to analyze the relation between SUVmax and the prognosis of the disease.Results There were relationships of SUV max with grade malignancy(P=0.0003),bone marrow involvement(P=0.003),tumor staging(P=0.021),lesion size(P=0.0001),necrosis(P=0.011),psLDH(P=0.0002)and positive rate of Ki-67(P=0.015).The relationships of SUV max with the lesion size,positive rate of Ki-67 and psLDH were positively correlated(r=0.737,0.615 and 0.691 respectively).A receiver operating characteristic(ROC)analysis demonstrated that the SUV max and psLDH distinguished reasonably well between aggressive and indolent disease(area under ROC curve,0.878 and 0.740 respectively).The variance analysis showed that the PET/CT treatment for 3 groups of SUV max were different,6.87±2.79,9.69±2.19,18.65±5.95,respectively,increasing with poor prognosis group.SUV max was significantly higher than the excellent prognosis with good prognosis group,and the results were statistically significant(P〈0.05).Conclusion SUV max is associated with several clinical pathological data.And SUV max with the lesion size,positive rate of Ki-67 and psLDH are positively correlated,the lesion size has most significant value in the levels of SUV max.SUV max is higher than psLDH in the diagnosis accuracy of aggressive lymphoma.The SUV max in different prognosis groups before treatment presents a gradually increasing tendency.
出处 《中国煤炭工业医学杂志》 2014年第11期1741-1745,共5页 Chinese Journal of Coal Industry Medicine
关键词 非霍奇金淋巴瘤 正电子发射计算机断层扫描 标准摄取值 乳酸脱氢酶 预后 Non-Hodgkin lymphoma Positron emission tomography-computed tomography Standardized uptake value Lactic dehydrogenase Prognosis
  • 相关文献

参考文献12

  • 1Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R- IPI) is a better predictor of outcome than the standard IPI for pa- tients with diffuse large B- cell lymphoma treated with R - CHOP[J]. Blood, 2007,109 (5) : 1857 - 1861.
  • 2Cheson BD, Pfistner B, Juweid ME, et al. Revised re- sponse criteria for malignant lymphoma[J]. J Clin Oncol,2007,25(5) :579 - 586.
  • 3Cheson BD. Role of functional imaging in the man- agement'of lymphoma [J]. J Clin Oncol, 2011, 29 (14) : 1844 - 1854.
  • 4Cohen MS, Arslan N, Dehdashti F, et al. Risk of ma- lignancy in thyroid incidentalomas identified by flu- orodeoxyglucose- positron emission tomography[J]. Surgery,2001,130(6) : 941 - 946.
  • 5Dimitrakopoulou - Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in pa- tients with colorectal' carcinoma[J]. Q J Nucl Med, 2003,47(1) :8- 13.
  • 6徐岚,陈芳源,钟华,黄洪晖,肖菲,韩晓凤,钟璐,朱坚轶,倪蓓文,陈涛.弥漫大B细胞淋巴瘤患者治疗前FDG-PET/CT检查与预后的相关性分析[J].内科理论与实践,2011,6(1):39-43. 被引量:7
  • 7牛奔,汪世存,胡冰,胡长路.PET/CT标准摄取值和LDH与非霍奇金淋巴瘤临床病理特征的相关性研究[J].临床肿瘤学杂志,2011,16(2):151-153. 被引量:15
  • 8黄岩,林桐榆,夏忠军,李志铭,管忠震.PET/CT在弥漫大B细胞淋巴瘤不同亚型中的应用[J].中国医药指南,2012,10(29):210-212. 被引量:3
  • 9Katzenberger T, Petzoldt C, Holler S, et al. The Ki67 proliferation index is a quantitative indicator of clini- cal risk in mantle cell lymphoma[J]. Blood,2006,107 (8) : 3407.
  • 10Papajik T, Myslivecek M, Sedova Z, et al. Standard- ised uptake value of 18F- FDG on staging PET/CT in newly diagnosed patients with different subtypes of non- Hodgkin's lyniphoma[J]. Eur J Haematol, 2011,86(1) :32 - 37.

二级参考文献28

  • 1Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome [J]. J Nucl Med, 2005, 46(6): 983-995.
  • 2Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors [J]. J Nucl Med, 2009, 50 Suppl 1: 122S- 150S.
  • 3Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: eoregistered FDG PET and CT at staging and restaging do we need contrast-enhanced CT? [J]. Radiology, 2004. 232(3): 823-829.
  • 4lsasi CR. Lu P, Blaufox MD. A metaanalvsis of ^18F-2- deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma[J]. Cancer, 2005. 104(5): 1066-1074.
  • 5Kirby AM, Mikhaeel NG. The role of FDG PET in the management of lymphoma: what is the evidenee base? [J]. Nuel Med Commun, 2007.28(5): 335-354.
  • 6Seam P. Juweid ME. Cheson BD. The role of FDG-PET seans in patients with lymphoma [J]. Blood, 2007, 110 (10): 3507-3516.
  • 7Schoder H, Nov A. G0nen M. et al. Intensity of ^18fluorodeoxyglueose uptake in positron emission tomography distinguishes between indolent and aggressive non- Hodgkin's lymphoma [J]. J Clin Oneol. 2005. 23(21): 4643-4651.
  • 8Sehn LH. Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J]. Blood, 2007, 109(5): 1857-1861.
  • 9Cheson BD, Pfistner B. Juweid ME. et al. Revised response criteria for malignant tymphoma [J]. J Clin Oncol,2007, 25(5): 579-586.
  • 10Ngeow JY, Quek RH, Ng DC, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma[J]. Ann Oneol. 2009,20(9): 1543-1547.

共引文献20

同被引文献54

  • 1董菲,克晓燕.侵袭性非霍奇金淋巴瘤治疗进展[J].中国实用内科杂志,2007,27(24):1894-1898. 被引量:1
  • 2Wang J,Sun NC,Nozama Y,et al.Histological and immunohis- to-chemical characterization of extranodal diffuse large-cell lymphoma as with prominent spindle cell features[J].Histopat hology,2001,39(5):476-481.
  • 3Kim SJ,Kim BS,Choi CW,et al.Ki-67 expression is predic- tive of prognosis in patients with stage I/II extranodal NK/T- cell lymphoma,nasal type [J].Annals of Oncology,2007,18: 1382-1387.
  • 4Szczuraszek K,Mazur G,Jelen M,et al.Prognostic Significance of Ki-67 Antigen Expression in Non-Hodgkin's Lymphomas[J].Anticancer research, 2008, 28:1113-1118.
  • 5Papajik T,Myslivecek M,Sedova Z,et al.Standardised uptake value of ,18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin' s lymphoma[J]. Eur J Haematol,2011,86(1): 32-37.
  • 6Paruno R,Zizzo N,Zito AF,et al.Microvascular density and endothelial area correlate with Ki-67 proliferative rate in the canine non-Hodgkin's lymphoma spontaneous model[J]. Leukemia Lymphoma,2006,47 : 1138-1143.
  • 7Broyde A,Boycov O,Strenov Y,et al.Role and prognostic significance of the Ki-67 index in non-Hodgkin's lym- phoma[J].American Journal of Hematology,2009,84 : 338- 343.
  • 8Watanabe R,Tomita N,Takeuchi K,et al.SUVMAX in FDG-PET at the biopsy site correlates with the proliferaion potential of tumor ceils in non-Hodgkin lymphoma[J]. Leuk Lymphoma,2010,51 (2):279-283.
  • 9马林峰,樊卫.淋巴瘤病灶对^(18)F-FDG摄取与不同病理亚型的关系[J].癌症,2009,28(4):425-430. 被引量:13
  • 10寿毅,陆建平,陈涛,马大烈,童林军,施一平,陈虞梅.PET/CT显像淋巴瘤病灶^(18)F-FDG摄取程度与肿瘤增殖性抗原Ki-67相关性研究[J].中国医学计算机成像杂志,2009,15(3):278-284. 被引量:5

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部